



The Digital Examiner **www.prostaidcalgary.org**

“Issue #284” June 2023

Annual General Meeting

Join us Tuesday June 13th for our Annual General Meeting which will be at the Danish Canadian Club (727 11 Ave SW, Calgary) starting at 7 pm and doors open at 6:30. There will be an assortment of hot & cold appetizers and refreshments provided as well as a cash bar. We need to know how many people are planning to come so we can inform the caterer by June 8th.

**Please RSVP To Richard at
program.director@prostaid.org**

What's New With Prostaid Calgary

Our April meeting at our new location, CKE Community Centre, located at 73rd Avenue and Elbow Drive SW, was very well attended with over 20 in-person guests enjoying a very informative message from our guest, Hal Eagletail.

We then followed up with a great meeting in May. There were about 20 in person guests and another dozen guests online to watch Dr. Tarek Bismar's virtual presentation. Dr. Bismar was able to answer questions afterwards and it was another first for PROSTAIID Calgary.

The Wives, Partners & Caregivers group and Warriors groups met socially over some pizza and reminisced about Pizza lunches of the past.

They then had time to meet separately in their respective rooms.



Donate Today

PROSTAIID Calgary is a registered charity that relies on the generosity of its members, supporters and friends to achieve its goals. Tax receipts are issued for all amounts over \$20.00.

Your donations are used to support our monthly journal (the Digital Examiner), our free online video library, our website, our outreach programs and general awareness.

Donate Today

Connect With Us

Information
Phone 403 455 1916
info@prostaid.org
Brad Sterling
President
president@prostaid.org

Connect With Us

Support Groups

Frank Altin
Warriors
faltin@telusplanet.net
Wives, Partners & Caregivers
Newly Diagnosed
info@prostaid.org

Meeting Info Here

Upcoming Events

July

“Even though there is not a General Meeting July 19th, we would like to invite the Warriors and Wives Partners & Caregivers to join us for a picnic at CKE Community Centre starting at 6:30. Enjoy

some food and fellowship followed by the separate group sharing and support.”

August

We have just confirmed Dr. Desmond Pink for our August 16th presentation.

Dr. Pink is the lead researcher in the development and validation of the Nanostics diagnostics platform and has considerable expertise in scientific team management, biochemistry, protein synthesis, and experimental therapeutics.

Volunteers are needed! We're putting together a volunteer list for our Casino Fundraiser Event scheduled for October 2nd and 3rd.

We have a brand new Casino this year, Ace Casino Airport. We are looking for volunteers for both days to fill the 1st shift from 11am-7:30pm and 2nd shift from 7pm- 3:15am. There are also positions available in the Count room both days from 11:15pm-3:30am.

Contact Richard for more info at

program.director@prostaaid.org

Articles Of Interest




Enzalutamide Ups Metastasis-Free Survival in nmHSPC

Combination treatment with enzalutamide with leuprolide is associated with improved metastasis-free survival compared with leuprolide therapy alone in patients with nonmetastatic hormone-sensitive prostate cancer (nmHSPC).

May 2023

Renal & Urology News

Enzalutamide



Improving immune responses in prostate cancer

In the current study, in an attempt to activate prostate cancer-killing immune cells, investigators at Johns Hopkins Hospital administered enoblituzumab to 32 men with high-risk prostate cancer prior to prostatectomy.

May 2023

Urology Times

Immunotherapy




MRI Guided Biopsies

This issue focuses on two major advances in imaging that should both have major impacts on the care men with prostate cancer receive.

April 2023

Prostatepedia

Imaging



FDA panel recommends limiting potential approval of olaparib/abiraterone to frontline BRCA+ mCRPC

The FDA's Oncologic Drugs Advisory Committee (ODAC) voted 11 to 1 recommending approval of olaparib (Lynparza) for use in combination with abiraterone acetate (Zytiga) and prednisone or prednisolone for the first-treatment of adult patients with BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC).

May 2023

Urology Times

BRCA+ mCRPC




Updated Findings Spur Excitement In nmCRPC, mHSPC, mCRPC

“There’s excitement that when physicians see the target, there’s a drug to get to the target--there’s a sense of satisfaction with that,” Elisabeth Heath, MD, FACP, said. “The world of genomic sequencing has changed what we do.”

May 2023

OncLive

Spur Excitement



Adding short-term ADT to dose-escalated RT does not improve survival in prostate cancer

Findings from the phase 3 NRG Oncology/Radiation Therapy Oncology Group (RTOG) 0815 study (NCT00936390) showed that adding short-term androgen deprivation (STAD) to dose-escalated radiotherapy did not improve overall survival (OS) in patients with intermediate-risk prostate cancer; however, the addition of STAD did improve secondary end points, including metastases rates, prostate cancer-specific mortality, and PSA failure..

May 2023

Urology Times

Adding ADT



Nivolumab Plus Brachytherapy/ADT Improves Disease Control in Grade Group 5 Prostate Cancer


Findings presented at the 2023 AACR Annual meeting showed that nivolumab plus HDR brachytherapy and ADT led to an 88% reduction in the 2-year risk of distant metastasis compared with historical control arms treated with standard-of-care therapy alone

May 2023

Onclive

Brachytherapy/ADT

Newly Diagnosed



Bone biomarkers found to be prognostic for overall survival in prostate cancer

Recent data from the randomized phase 3 SWOG S1216 study show that high levels of certain bone turnover biomarkers are associated with earlier mortality in men newly diagnosed with hormone-sensitive prostate cancer (HSPC).

May 2023

Urology Times

Bone Biomarkers



Dr. Bradley Gill on key BPH research from AUA 2023

In this video, Bradley Gill, MD, MS, recaps several presentations on benign prostatic hyperplasia from the 2023 American Urological Association Annual Meeting in Chicago, Illinois.

May 2023

Urology Times

BPH Research

Thank you to our Sponsors and Community Partners



Read more articles below

For Caregivers & Families



When a Loved One has Cancer - Ten Ways to Support Someone with a Cancer Diagnosis

Family and friends of people with a cancer diagnosis often feel powerless in the heart-felt attempts to be supportive. Oncologist Rob Rutledge offers the background and practical advice about how to support people affected by cancer.

September 2022

Canadian Cancer Survivor Network

Support

Articles For Everyone



Link Between PSA Response and Survival Outcomes Supports Use of Darolutamide Plus ADT/Docetaxel as a SOC in mHSPC

Fred Saad, MD, FRCS, expands on the relationship between PSA responses and survival outcomes in the ARASENS trial, explained the use of 0.2 ng/mL as a standard cut off for undetectable PSA within this exploratory analysis, and discussed how this study elucidates future directions for research with triplet regimens in mHSPC.

May 2023

OncLive

PSA Response



Newly Identified Prostate Cancer Subtypes May Respond Differently to Treatment

Researchers say they have identified 4 subtypes of prostate cancer with distinct biological and clinical features, and these subtypes may respond differently to treatment.

May 2023

Renal & Urology

Respond Differently

New Videos



PSA Response and Time to PSA Progression With Abiraterone Acetate and Olaparib in mCRPC

Primary results from the phase 3 PROpel trial (NCT03732820) demonstrated improved radiographic progression-free survival with the combination of abiraterone acetate and olaparib compared with abiraterone acetate alone as frontline therapy in all-comers with mCRPC (HR, 0.66, 95% CI, 0.54-0.81; $P < .001$).

May 2023

OncLive

PSA Response



How Does Prostate Cancer Spread to the Bones? | Spot & Injectable Radiation

Medical oncologist Mark Scholz, MD, goes into more depth about the newest scans and treatments available for men with advanced prostate cancer. He describes the various contexts in which any one of these treatments would or would not be included in a patient's treatment plan, and some of the factors involved in fine-tuning each patient's upfront treatment to maximize the odds of achieving a long, durable remission.

April 2023
PCRI

[Spot & Injectable Radiation](#)

Treatment and Research Considerations for Basal Cell Carcinoma of the Prostate

Dr Haffner explained distinguishing features between basal cell and adenocarcinoma of the prostate, findings from a genomics study of basal cell prostate carcinoma, and the challenges that arise when diagnosing and treating patients with this rare disease.


May 2023
OneLive

[Listen To The Podcast Here](#)



Sexuality after Prostate Cancer

Tom Baker Cancer Center Nurse Practitioner Reanne Booker comes back for another arousing discussion about the sexual realities and outcomes after prostate cancer. She gives a good overview of how prostate cancer treatments affect male sexual function and then goes to describe in detail the available options.
Prostaaid Calgary



[Watch Video Here](#)

P.O. Box 72126
R.P.O. Glenmore Landing
Calgary, Alberta T2V 5H9



[Unsubscribe](#)